BridgeBio Pharma (NASDAQ: BBIO) Priced a 5,000,000-Share Secondary Offering of Common Stock on Friday August 14, 2026 on Behalf of Selling Stockholder KKR Genetic Disorder L.P. at the August 13 Closing Price of $81.21 per Share, Implying Roughly $406 Million in Proceeds to KKR (BridgeBio Is Not Selling Any Shares and Will Not Receive Any of the Proceeds); The Offering Is Expected to Close August 17 With William Blair, Goldman Sachs & Co. LLC, and KKR Capital Markets LLC as Joint Book-Running Managers; The BridgeBio Commercial Franchise Includes Infigratinib, the Weekly-Dosing FGFR Inhibitor for Achondroplasia That Competes Directly Against BioMarin's Voxzogo (Vosoritide, Daily Subcutaneous CNP Analog) and Ascendis's Newly-Launched YUVIWEL (Weekly TransCon C-Type Natriuretic Peptide), Positioning the Company at the Center of the Newly Competitive Pediatric Achondroplasia Commercial Category
BridgeBio Pharma (NASDAQ: BBIO) priced a 5,000,000-share secondary offering of common stock on Friday August 14, 2026 on behalf of selling stockholder KKR Genetic Disorder L.P. at the August 13 closing price of $81.21 per share on Nasdaq. The implied secondary-market proceeds to KKR total roughly $406 million. BridgeBio is not selling any shares and will not receive any of the proceeds; the transaction diversifies BridgeBio's institutional shareholder base as KKR reduces its position following a multi-year holding period. The offering is expected to close August 17, 2026 with William Blair, Goldman Sachs & Co. LLC, and KKR Capital Markets LLC as joint book-running managers. The BridgeBio commercial franchise includes infigratinib, the weekly-dosing FGFR inhibitor for achondroplasia that competes directly against BioMarin's Voxzogo (vosoritide, daily subcutaneous C-type natriuretic peptide analog) and Ascendis's newly-launched YUVIWEL (weekly TransCon C-type natriuretic peptide). The three-way competitive dynamic in pediatric achondroplasia now involves daily-injectable (Voxzogo), weekly-injectable peptide (YUVIWEL), and weekly-oral small-molecule (infigratinib) options, and the BridgeBio franchise is positioned at the small-molecule end of that spectrum. Although infigratinib is not itself a peptide analog, the achondroplasia commercial category is one of the fastest-growing peptide-adjacent pediatric-rare-disease indications following the July 8, 2026 New England Journal of Medicine publication of the Ascendis TRANSCEND trial results and the June 2026 YUVIWEL FDA approval.